CytRx Corp
CYTR
CYTR was delisted on the 3rd of June, 2019.
2 hedge funds and large institutions have $2K invested in CytRx Corp in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
33% less funds holding
Funds holding: 3 → 2 (-1)
90% less capital invested
Capital invested by funds: $20K → $2K (-$18K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BMO
Beck Mack & Oliver
New York
|
-$12K |
CYTR Hedge Fund Activity: Q2 2022 in Review
2 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in CytRx Corp (CYTR) for Q2 2022, worth a combined $2K — down 90% from $20K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CYTR and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Beck Mack & Oliver, exiting entirely with an estimated $12K sold.
- 2 institutional investors held CytRx Corp (CYTR) as of Q2 2022, down from 3 in Q1 2022.
- Funds reported $2K of CytRx Corp stock for Q2 2022, down 90% quarter-over-quarter.
- 0 funds opened new CytRx Corp positions in Q2 2022 and 1 closed out, a net change of -1 holder.
- The largest CytRx Corp seller in Q2 2022 was Beck Mack & Oliver, an estimated $12K sold.
Based on aggregated 13F filings for Q2 2022.